- BBG Advanced Therapies and CELLforCURE have partnered to provide transatlantic manufacturing solutions for Advanced Therapy Medicinal Products (ATMPs), connecting U.S. and European capacities.
- The collaboration offers integrated CDMO services, supporting early-stage development through full-scale commercial production, including GMP-compliant manufacturing, donor management, and quality control.
BBG Advanced Therapies (BBGAT), a subsidiary of BioBridge Global, has partnered with CELLforCURE, part of SEQENS Group, to provide transatlantic manufacturing solutions for Advanced Therapy Medicinal Products (ATMPs). The collaboration enables U.S. companies to access CELLforCURE’s European facilities, while European companies can leverage BBGAT’s U.S.-based capacities, creating an integrated global CDMO network.
BBGAT offers expertise in cell and tissue therapies, supporting projects from early-stage development through late-phase readiness and market launch. Its facilities include nine cGMP cleanrooms spanning 558 m² and 232 m² of process development space, as well as the world’s only mobile leukapheresis centre. The company has experience in MSC-based therapies and complies with FDA, EMA, and PMDA regulations, providing services such as leukapheresis, donor management, testing, cryopreservation, biomanufacturing, and assay development.
CELLforCURE provides EMA-authorized and FDA-compliant manufacturing, with a 10,000 m² facility that includes 3,000 m² of GMP-certified areas across seven independent manufacturing lines and 56 cleanrooms. The company has extensive experience in CAR-T and immune cell therapies, performing 90% of quality control processes in-house to ensure high-quality drug products.
The partnership aims to remove barriers in ATMP manufacturing, offering fully scalable solutions to support multinational trials and accelerate the journey from concept to commercialization. By combining transatlantic expertise, infrastructure, and regulatory compliance, the collaboration enhances global capacity and provides therapy developers with comprehensive, end-to-end CDMO support.
